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Safety and Efficacy of Drug-Eluting Balloons in the Treatment  
of Drug-Eluting In-Stent Restenosis: Experience of a  
Tertiary Care Hospital
Sajid Dhakam, MD1,  Asif Jafferani, MBBS2,  Hafeez Ahmed, MBBS1,  Nasir Rahman, MBBS1,  Ambreen Gowani, BScN1
ABSTRACT: Background. The advent of drug-eluting bal-
loons (DEBs) is a promising development for coronary revas-
cularization procedures, especially for in-stent restenosis (ISR). 
This study aims to highlight our experience with DEBs in the 
treatment of drug-eluting ISR at a tertiary care hospital in Paki-
stan. Methods. All patients presenting to our institution from 
August 2008 to February 2011 with significant drug-eluting in-
stent restenosis (DES-ISR) who were eligible to receive treatment 
via DEB were included in the analysis. Patient baseline character-
istics and angiographic data about the lesion characteristics were 
obtained. Postprocedural and follow-up endpoints, including car-
diac death, myocardial infarction, and repeat revascularization, 
ie, major adverse cardiovascular events (MACE), were included 
in the analysis. Results. A total of 26 patients received treatment 
with DEB in the study period, with a significant number having 
major predisposing factors for the development of ischemic heart 
disease (IHD; 46% diabetics; 92% hypertensives). The culprit 
lesion was most commonly identified in the left anterior descend-
ing (31%), with presence of American College of Cardiology/
American Heart Association lesion type C in 68% of patients. 
The SeQuent Please paclitaxel-eluting balloon (B. Braun) was 
used for revascularization. Patients were followed for a median of 
16 months. Only 5 patients (19%) developed MACE during this 
period. Conclusion. Our experience demonstrates the effective-
ness of DEBs in the treatment of drug-eluting ISR, especially in 
complex lesions with patients having significant risk factors for 
development of IHD. However, further studies are needed to de-
fine their indications in this role. 
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 The drug-eluting balloon (DEB) was designed1 to ad-
dress the incumbent issues of neointimal proliferation and 
stent thrombosis, which are the banes of the established 
technology of the bare-metal stent (BMS) and drug-eluting 
stent (DES).2,3 Theoretically, this device could deliver the 
drug evenly to the vessel wall, limiting neointimal prolifer-
ation and at the same time reducing dependency on long-
term anti-platelet therapy for vessel patency.4 This concept 
tested favorably in preclinical studies, with adequate deliv-
ery of drug from balloon (~90% in 1 minute of inflation),1 
and significant reduction in areas of neointimal prolifera-
tion,1,5,6 diameter stenosis, and late luminal loss.7 Clinical 
studies following them are limited; however, they clearly 
demonstrate a favorable reduction in late luminal loss, 
restenosis rates, and major adverse cardiovascular events 
(MACE) in de novo8 and bifurcation lesions.9 However, 
their efficacy in lesions with in-stent restenosis (ISR) is the 
most promising,10,11 and as such, needs further research to 
define the adequate place of the DEB in the intervention-
alist’s armament.12 Hence, this registry aims to determine 
the safety and efficacy of the use of DEBs in patients with 
drug-eluting ISR at a tertiary care hospital in Pakistan.
The SeQuent Please DEB (B. Braun) was used primar-
ily in this study. It is a coated balloon delivering paclitaxel 
directly to the lesion site. Paclitaxel 3 µg/mm3 is embedded 
in a hydrophilic, bioabsorbable matrix which, after balloon 
deflation, adheres to the vessel wall to allow prolonged 
drug delivery to the lesion site.4 
Methods
Registry setup. The Aga Khan University Hospital 
(AKUH) in Karachi is a major tertiary care hospital serving 
more than 10 million people of Karachi and the surround-
ing region.13 The registry was approved by the Institution’s 
Ethics Review Committee. The registry did not receive any 
external funding. All the patients gave written informed 
consent for the procedure.
Inclusion/exclusion criteria. All patients who presented to 
our Institute during the period from August 2008 to February 
2011 with angiographic evidence of >50% luminal diameter ste-
nosis ISR with clinical or imaging evidence of ischemia, or >70% 
luminal narrowing of ISR in the absence of evidence of ischemia 
in their prior implanted DES, who subsequently underwent 
treatment with DEB were included. Patients with narrowing in 
the prior balloon only treated segments were excluded. 
Procedural details. All patients received 300 mg aspi-
rin and 300 mg clopidogrel 6 hours preprocedure and had 
intravenous heparin administered to maintain activated 
clotting time at >250 seconds during the procedure. Ad-
ministration of glycoprotein IIb/IIIa inhibitors was left to 
the physician’s discretion.
Technique. A lesion deemed sutiable for treatment with 
DEB was first prepared with either a compliant or a non-
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compliant balloon as per requirement to fully expand the 
lesion in order to achieve its maximal luminal diameter, 
according to the reference vessel diameter. DEB was used 
as the last step for the lesion treatment with no further bal-
looning done after DEB to ensure maximum availability of 
the drug delivered to the vessel wall. The balloon-to-artery 
ratio for the study subjects was kept at 0.9:1. The DEB 
was inflated at the site of ISR for 60 seconds at its nominal 
pressure. If the lesion length was large and such a size was 
not available, then two short-length DEBs were used se-
quentially to completely cover the lesion. Angioplasty was 
considered adequate at <20% residual stenosis.
Follow-up and endpoints. All patients were followed in 
the clinic post discharge. MACE included all postprocedural 
cardiac deaths, myocardial infarctions (MIs), and need for re-
peat revascularization.
Statistical analysis. Statistical analysis was carried out 
using SPSS version 17.0 (SPSS Inc). Continuous variables 
were presented as mean ± standard deviation (SD) or me-
dian ± interquartile range (IQR) and categorical variables 
were presented as numbers (percentages). No confirmatory 
analysis was performed.
Results
A total of 26 patients with DES-ISR underwent revas-
cularization using DEB during the study period. Baseline 
patient characteristics of those having ISR are given in 
Table 1. Hypertension and diabetes were identified as im-
portant risk factors.
Most patients had more than 1 diseased vessel and the 
target vessel most frequently revascularized was the left 
anterior descending (LAD) artery. Morphology and lesion 
characteristics are given in Table 2, while procedure-related 
details of the DEB used are given in Table 3. No patient 
required stenting at the lesion treated with DEB.
In-hospital results. No acute postprocedural complica-
tions were observed, including no-reflow and dissection. 
During the hospital stay, 1 patient developed cardiogenic 
shock and died. No other patients developed MACE; how-
ever, 4 patients still had angina symptoms and were man-
aged medically.
Follow-up results. Patients were followed for a median 
of 16 months; during this time, 8 patients continued to re-
main symptomatic, of which 4 patients developed MACE, 
with 1 presumed cardiac death and 3 revascularizations. 
Therefore, the total MACE rate was 19%. There were also 
2 deaths due to proven non-cardiac causes in the follow-
up period; 1 with epidural tuberculous abscess and 1 sec-
ondary to cerebral hemorrhage almost 1.5 years after the 
procedure. The remaining patients considered symptom-
atic had complaints of chest discomfort, with no objective 
evidence for the presence of ischemia or MI. Details of the 
above, including MACE rates, are given in Table 4.
Discussion
DEB development has been one of the most promising 
approaches for the treatment of ISR lesions. In the first 
clinical study for DEB, the PACCOCATH ISR I trial, the 
paclitaxel-eluting balloon was compared with an uncoated 
balloon for the treatment of coronary ISR. Six-month post-
Table 1. Patient characteristics with those having DES-ISR. 
Characteristic Patients 
(n = 26)
Age (years) 65.69 ± 12.74
Male 21 (80.8%)
Diabetic 12 (46.2%)
Hypertensive 24 (92.3%)
Dyslipidemic 7 (31.8%)
Chronic kidney disease 4 (18.2%)
Data given as mean ± standard deviation or mean (percentage).
Table 2. Morphology and lesion characteristics of patients 
with ISR treated with DEB.
Characteristic n = 26
Vessel diffusely diseased 12 (46.2%)
Ostial target lesion 4 (15.4%)
Bifurcation lesion 5 (19.2%)
Evidence of calcification 14 (53.8%)
Intracoronary thrombus 2 (7.7%)
Severe tortuosity 4 (15.4%)
Coronary artery disease
   Single-vessel disease 5 (20.8%)
   2-vessel disease 8 (33.3%)
   3-vessel disease 11 (45.8%)
Treated vessel
   Right coronary artery 6 (23.1%)
   Left circumflex 7 (26.9%)
   Left anterior descending 8 (30.8%)
   Saphenous vein graft 2 (7.7%)
   Left main 1 (3.8%)
   Obtuse marginal 1 (3.8%)
   Diagonal 1 (3.8%)
Stenosis (%) 91.92 ± 9.52
Mean lesion length (mm) 25.63 ± 11.97
Lesion type
   A 0 (0%)
   B1 3 (12%)
   B2 5 (20%)
   C 17 (68%)
Vessel diameter (mm) 3 ± 0.24*
Data given as numbers (percentages), mean ± standard deviation, or 
*median ± interquartile range.
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angiography follow-up showed a significantly decreased late 
lumen loss in the coated balloon groups.10 Results of the 
PACCOCATH ISR I and II trials, both of which had iden-
tical protocols, were pooled to get a larger sample size and 
longer follow-up period. These results further confirmed the 
previous, with lower rates for binary restenosis and MACE 
in the coated-balloon group until 2 years.11
However, the real question remained about the relative ef-
ficacy and safety of the DEB as compared to the DES, which 
is the standard of care in lesions with ISR. This was answered 
in the PEPCAD II trial, comparing the SeQuent Please pa-
clitaxel-eluting balloon with a paclitaxel-eluting stent (Taxus 
Liberté) in lesions with ISR. At 6-month follow-up, the trial 
showed a lower late lumen loss in the DEB group, with lower 
binary restenosis rates.14 Thus, the DEB was at least as safe 
and efficacious as the DES in patients with ISR.
It must be remembered that while the PEPCAD II trial en-
rolled patients with ISR in BMS,14 data are still accumulating 
on the role of DEB in DES-ISR. It is well known that ISR 
occurring in DES is more difficult to treat, with further DES 
in this situation also having higher MACE and revasculariza-
tion rates.15-17 A recent report by Raja et al demonstrates their 
experience in the use of SeQuent Please DEB in the treatment 
of DES-ISR  for bifurcating lesions.18 Further experience comes 
for another DEB technology with the Dior (Eurocor), which 
was evaluated by a Spanish multicenter registry evaluating 
1-year outcomes for ISR in both BMS as well as DES.19 Results 
were favorable in both groups, with a MACE rate of 16.7%; 
however, the DES group had a non-significant trend toward 
higher MACE at 1 year. In the same vein, a larger multicenter 
registry published their data on the use of the Dior in ISR le-
sions in BMS as well as DES.20 Their results also demonstrated 
a favorable cumulative MACE rate of 11.5% at 7.5 months 
follow-up. Recent studies on the SeQuent Please include the 
PEPCAD-DES, and data from this trial reported at the Trans-
catheter Cardiovascular Therapeutics (TCT) 2011 conference 
showed the SeQuent Please to be superior to plain old balloon 
angioplasty in preventing late lumen loss (0.43 ± 0.61 mm vs 
1.03 ± 0.77 mm, respectively; P<.001) and binary restenosis 
(17.2% vs 58.1%, respectively; P<.001) in DES-ISR lesions at 
6-month angiographic follow-up.21
As this is a relatively new technology, DEBs have not 
been adequately evaluated in different patient populations 
with different risks and baseline characteristics. Of note is 
the fact that in this registry, there was a significantly larger 
number of patients with diabetes as compared to the patient 
populations enrolled in the previously discussed trials. Dia-
betes is known to be a risk factor for developing ISR,19,22,23 
and results from this study support the fact that the DEB 
prevents development of binary restenosis in patients with 
diabetes, among other cardiovascular risk factors. Further-
more, patients had fairly complex lesions and this may have 
resulted in the slightly higher rate for MACE as compared 
to those reported in other registries.
Study limitations. This study has several limitations 
that must be taken into account. The registry size was rela-
tively small; thus, it may not reflect all the ramifications 
of treatment with DEB for such patients. However, since 
research into the role of DEBs in treating DES-ISR lesions 
is still in its infancy, it remains for designed well-powered 
trials to truly establish its role for this indication. Also, 
our patients did not undergo follow-up angiography to 
determine if the procedure had remained successful and 
thus, those who presented with mortality may not actually 
have the DEB-treated lesion as the culprit for MACE. This 
follow-up was, however, beyond the resources of this study.
Conclusion
The DEB appears to be a promising technology for ISR, 
especially of the DES. Our experience, however, illustrates 
the need for further evidence in terms of randomized trials 
in different patient populations with results stratified to 
take into account established risk factors for ISR, and fur-
ther elucidation of patient characteristics of those develop-
ing MACEs and mortality after the DEB procedure, before 
Table 3. Procedural details of DEB use in ISR.
Procedure n = 26
Balloon size x length (mm)
   2.5 x 17 2
   2.5 x 26 2
   2.75 x 20 1
   3.0 x 17 1
   3.0 x 20 3
   3.0 x 26 5
   3.0 x 30 5
   3.25 x 26 1
   3.25 x 30 1
   3.5 x 26 2
   3.5 x 30 3
Residual stenosis (%) 11.54 ± 9.25
Data given as numbers or mean ± standard deviation.
Table 4. Complications in patients undergoing revasculariza-
tion with DEB.  
Complication In-Hospital 
Rates  
(n = 26)
At 
Follow-up 
(n = 25)
Bleeding 1 (3.8%) —
Angina symptoms 4 (15.4%) 8 (32%)
Postprocedural mortality
   Cardiac
   Non-cardiac
1 (3.8%)
—
1 (4%)
2 (8%)
CABG required — 3 (12%)
RePTCA required —
CABG = coronary artery bypass graft; PTCA = percutaneous 
transluminal coronary angioplasty.
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its indications can be better identified to serve the patient 
population at large.
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